Choledochoscope manometry about different drugs on the Sphincter of Oddi

Kong, Jing; Wu, Shuodong; Zhang, Xiaobo; Li, Zhensheng; Su, Gang; Wang, Wei; Chen, Junzhi

doi:10.3748/wjg.14.5907

Cited by 5 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Abnormalities in SO contractility are thought to be related to the high incidence of biliary infections and cholelithiasis. 4 Given the increasing acceptance of these minimally invasive surgical procedures, what changes will occur with respect to the management of patients with choledocholithiasis? In this study we compared the SO pressure changes and stone recurrence rates after surgery in patients with choledocholithiasis who underwent LCBDE during LC or EST with LC, which may provide clinical evidence for patients with choledocholithiasis and physicians to choose the most appropriate minimally invasive surgical approach.…”

Section: Discussionmentioning

confidence: 99%

A Randomized, Clinical Trial Involving Different Surgical Methods Affecting the Sphincter of Oddi in Patients With Choledocholithiasis

Yin

Gao²,

Zang³

et al. 2016

Surgical Laparoscopy, Endoscopy &Amp; Percutaneous Techniques

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

A Randomized, Clinical Trial Involving Different Surgical Methods Affecting the Sphincter of Oddi in Patients With Choledocholithiasis

Yin

Gao²,

Zang³

et al. 2016

Surgical Laparoscopy, Endoscopy &Amp; Percutaneous Techniques

View full text Add to dashboard Cite

show abstract

“…[ 20 ] In addition, gabexate has a specific effect on relieving Oddi sphincter spasms. [ 40 ] However, Andriulli et al [ 41 , 42 ] have shown that gabexate cannot effectively prevent the occurrence of PEP in either ordinary or high-risk patients. At present, the opinion of Japanese experts is that although gabexate can prevent the occurrence of PEP, it must be used in a large dose (1 g) and for a long time (12 hours).…”

Section: Discussionmentioning

confidence: 99%

Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis based on prospective, randomized, and controlled trials

Xie,

Cheng,

Deng

et al. 2023

Medicine

View full text Add to dashboard Cite

Objectives: To evaluate the efficacy of nafamostat mesilate in the prevention of post–endoscopic retrograde cholangiopancreatography pancreatitis (PEP) by conduct a systematic review and meta-analysis. Method: We retrieved for all randomized controlled trials (RCTs) about compare nafamostat mesilate with placebo in preventing PEP published before August 23, 2022, in 5 major electronic databases. The primary outcome was PEP rate, and the secondary outcome was post-ERCP hyperamylasemia (PEHA) rate. Subgroup analyses were performed to reveal the factors that may affect the preventive effect of nafamostat. Assessment of the quality of evidence was conducted based on Grading of Recommendations, Assessment, Development and Evaluations (GRADE) system. Results: According to the search strategy and criteria of inclusion and exclusion, 8 articles with a number of 3210 patients were included. The PEP incidence of the nafamostat group was inferior compared with the placebo group (4.6% vs 8.5%, RR = 0.50, 95% CI: 0.38–0.66). Subgroup analyses revealed that nafamostat had a preventive effect on patients with different risk stratification (High-risk: RR = 0.61, 95% CI: 0.43–0.86, Low-risk: RR = 0.28; 95% CI: 0.17–0.47). Different doses (20 mg: RR = 0.50, 95% CI: 0.36–0.69, 50 mg: RR = 0.45, 95% CI: 0.27–0.74) and duration (<12 hour: RR = 0.55, 95% CI: 0.37–0.81, ≥12 h: RR = 0.44, 95% CI: 0.29–0.66) of administration of nafamostat are adequate for the prevention of PEP, but postoperative administration may not help (preoperative: RR = 0.52, 95% CI: 0.39–0.69, postoperative: RR = 0.54, 95% CI: 0.23–1.23). Nafamostat may not efficacious in preventing severe PEP (Mild: RR = 0.49, 95% CI, 0.35–0.68, Moderate: RR = 0.47, 95% CI: 0.25–0.86, Severe: RR = 0.91, 95% CI, 0.25–3.29) or in low-quality studies (Low-quality: RR = 0.69, 95% CI: 0.13–3.60, High-quality: RR = 0.49, 95% CI: 0.37–0.65). Conclusion: Preoperative use of nafamostat can effectively prevent PEP in patients with various risk stratification. Nafamostat can prevent mild and moderate PEP, but may not prevent severe PEP and PEHA. There should be more high-quality RCTs in future to strengthen the evidence of nafamostat in preventing PEP.

show abstract

“…The main bile duct stores the bile that is secreted continuously by the liver, to expel it only a few times a day during meals. During this storage period, the main bile duct endures large radial distension, with an increased pressure, which can explain its softer behavior in this direction (Kong, 2008;W. C. Li et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

Biomechanical behaviour of human bile duct wall and impact of cadaveric preservation processes.

Girard

Chagnon

Gremen³

et al. 2019

Journal of the Mechanical Behavior of Biomedical Materials

View full text Add to dashboard Cite

Biliary diseases are the third most common cause of surgical digestive disease. There is a close relationship between the mechanical performance of the bile duct and its physiological function. Data of biomechanical properties of human main bile duct are scarce in literature. Furthermore, mechanical properties of soft tissues are affected by these preservation procedures. The aim of the present work was, on the one hand, to observe the microstructure of the human bile duct by means of histological analysis, on the other hand, to E. Girard a,c,d,*

show abstract

Choledochoscope manometry about different drugs on the Sphincter of Oddi

Cited by 5 publications

References 18 publications

A Randomized, Clinical Trial Involving Different Surgical Methods Affecting the Sphincter of Oddi in Patients With Choledocholithiasis

A Randomized, Clinical Trial Involving Different Surgical Methods Affecting the Sphincter of Oddi in Patients With Choledocholithiasis

Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis based on prospective, randomized, and controlled trials

Biomechanical behaviour of human bile duct wall and impact of cadaveric preservation processes.

Contact Info

Product

Resources

About